Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366157 | 0.88 | ALOX15 (0.43) | POLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12366131 | 0.86 | DHODH (0.38) | TDP1POLBDHODHKMT2ATTR | |
| SCHEMBL12366599 | 0.85 | HTR2B (0.42) | — | |
| SCHEMBL12365912 | 0.83 | TDP1 (0.41) | TDP1POLBKMT2ATTRPTPRC | |
| SCHEMBL12366143 | 0.81 | TDP1 (0.39) | TDP1POLBKMT2ATTRPTPRC | |
| SCHEMBL12366277 | 0.80 | TDP1 (0.39) | TDP1POLBKMT2ATTRTBXA2R | |
| SCHEMBL12365227 | 0.79 | TDP1 (0.42) | TDP1POLBKMT2ATTRPTPRC | |
| SCHEMBL12366182 | 0.79 | TDP1 (0.42) | TDP1POLBKMT2ATTRPTPRC | |
| SCHEMBL12366147 | 0.79 | KMO (0.39) | TDP1TTRPTPRC | |
| SCHEMBL12366132 | 0.78 | TTR (0.43) | TDP1KMT2ATTRPTPRCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | TDP1 378/4885NAPRT 1780/4885POLB 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.